Webcast on Tuesday, July twenty third at 8:30 AM Japanese will embody updates on Jaguar’s most cancers supportive care portfolio, together with participation from Jaguar scientific staff, affected person advocates, and main oncology consultants on most cancers therapy-related diarrhea (CTD) and oral mucositis; Click on right here to register for webcast
Jaguar expands Make Most cancers Much less Shitty (MCLS) affected person advocacy program to include choose group of MCLS Ambassadors – most cancers survivors who perceive the realities of most cancers and are now not prepared to just accept debilitating unintended effects of most cancers therapies as a suitable trade-off for survival
Most cancers sufferers with diarrhea are 40% extra more likely to discontinue their remedy; oral mucositis impacts as much as 40% of sufferers present process chemotherapy and roughly 90% of these receiving chemoradiation for head and neck cancers, with greater than one-third of sufferers discontinuing most cancers remedy due to the situation
SAN FRANCISCO, CA / ACCESSWIRE / July 18, 2024 / Jaguar Well being, Inc. (NASDAQ:JAGX) (“Jaguar”) right now introduced that it’ll maintain an investor webcast on Tuesday, July 23, 2024 at 8:30 AM Japanese to assessment outcomes for the corporate’s pivotal section 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in grownup most cancers sufferers with stable tumors receiving focused remedy, with or with out commonplace chemotherapy. A press launch asserting the outcomes will probably be issued that morning, previous to the webcast. The webcast will present updates on Jaguar’s advancing most cancers supportive care portfolio and embody members of Jaguar’s scientific staff, affected person advocates, and main oncology consultants on two of the most typical and insupportable unintended effects of most cancers remedy: CTD and oral mucositis.
Participation Directions for Investor Webcast
When: Tuesday, July 23, 2024 at 8:30 AM Japanese
Participant Registration & Entry Hyperlink: Click on Right here
“Sufferers are the guts of our mission at Jaguar,” mentioned Lisa Conte, the corporate’s president and CEO. “We sit up for receiving and offering the OnTarget outcomes with the anticipation we all know all our stakeholders share.”
Along with the forthcoming OnTarget knowledge, the next advances in Jaguar’s most cancers supportive care portfolio will probably be mentioned through the webcast on July 23:
-
In April 2024, Jaguar entered into an unique 5-year U.S. in-license settlement for the FDA-approved oral mucositis prescription product, Gelclair®. Jaguar’s promotion of Gelclair started at this yr’s Oncology Nursing Society (ONS) Congress and the American Society of Medical Oncology (ASCO) Annual Assembly.
-
Jaguar has expanded its affected person led advocacy program – “Make Most cancers Much less Shitty” (MCLS) to include a choose group of MCLS Ambassadors. The MCLS marketing campaign is designed to offer a voice to most cancers survivors who’re now not prepared to just accept debilitating unintended effects of most cancers therapies as a suitable trade-off for survival. The MCLS Ambassadors – most cancers survivors who perceive the realities of most cancers – will help this system by serving to unfold the MCLS message inside the most cancers neighborhood. Study extra in regards to the Make Most cancers Much less Shitty program at makecancerlessshitty.com and on X, Fb & Instagram.
“Whereas most cancers therapies have superior significantly because the creation and availability of focused therapies, vital short- and long-term remedy unintended effects may be difficult and even devastating to a person’s high quality of life,” mentioned Stacey Tinianov, 11-year most cancers survivor and founding father of Advocates for Collaborative Training. Tinianov serves on the corporate’s Scientific Advisory Board and is heading up Jaguar’s Make Most cancers Much less Shitty marketing campaign. “Supportive care throughout remedy is essential for sustaining dignity and well-being. No facet impact, whether or not excessive fatigue, extreme diarrhea, mouth sores, persistent ache, or the rest, ought to ever be thought of ‘acceptable’ or ‘tolerable.'”
About Crofelemer
Crofelemer is the one oral prescription drug accepted beneath FDA botanical steerage. It’s plant-based, extracted and purified from the pink bark sap of the Croton lechleri tree within the Amazon rainforest. Jaguar household firm Napo Prescribed drugs has established a sustainable harvesting program, beneath truthful commerce practices, for crofelemer to make sure a excessive diploma of high quality, ecological integrity, and help for Indigenous communities. The OnTarget examine is testing whether or not crofelemer (versus placebo) can stop (or considerably cut back) diarrhea when any one of many chosen 24 focused therapies (which can be related to diarrhea in no less than 50% of sufferers) is initiated.
Picture of Croton lechleri tree, the supply of crofelemer
About Most cancers Remedy-Associated Diarrhea (CTD)
Diarrhea is a standard facet impact of focused therapies and new therapies are wanted. As much as 95% of sufferers on tyrosine kinase inhibitors (TKIs) undergo from diarrhea, relying on the TKI used.1 Greater than 2 million persons are anticipated to be identified with most cancers in 2024 within the U.S., in keeping with the American Most cancers Society.2 Most cancers sufferers with diarrhea have been proven to be 40% extra more likely to discontinue their focused remedy.3
About Oral Mucositis
Oral mucositis is a standard, painful, and debilitating most cancers treatment-related facet impact.4 As much as 40% of all sufferers handled with chemotherapy develop oral mucositis, and this share rises to roughly 90% for sufferers with head and neck cancers handled with chemotherapy and radiotherapy.5 Of the latter, 19% could find yourself being hospitalized, which can negatively impression high quality of life and improve healthcare utilization prices.5 Oral mucositis is a dose-limiting facet impact of most cancers remedy, with greater than one-third of sufferers discontinuing remedy due to the situation.6
Oral mucositis may cause an incapability to eat or discuss, and an elevated danger of an infection. It could additionally lead to remedy delays or dose reductions to handle signs.4
Concerning the Jaguar Well being Household of Corporations
Jaguar Well being, Inc. (Jaguar) is a industrial stage prescription drugs firm targeted on creating novel proprietary prescription medicines sustainably derived from vegetation from rainforest areas for folks and animals with gastrointestinal misery, particularly related to overactive bowel, which incorporates signs reminiscent of persistent debilitating diarrhea, urgency, bowel incontinence, and cramping ache. Jaguar household firm Napo Prescribed drugs (Napo) focuses on creating and commercializing human prescription prescription drugs for important supportive care and administration of uncared for gastrointestinal signs throughout a number of sophisticated illness states. Napo’s crofelemer is FDA-approved beneath the model title Mytesi® for the symptomatic reduction of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral remedy. Crofelemer is also the topic of Napo’s section 3 OnTarget scientific trial for preventive remedy of most cancers therapy-related diarrhea (CTD). Jaguar household firm Napo Therapeutics is an Italian company Jaguar established in Milan, Italy in 2021 targeted on increasing crofelemer entry in Europe and particularly for orphan and/or uncommon ailments. Jaguar Animal Well being is a Jaguar tradename. Magdalena Biosciences, a three way partnership fashioned by Jaguar and Filament Well being Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is concentrated on creating novel prescription medicines derived from vegetation for psychological well being indications.
For extra details about:
Jaguar Well being, go to https://jaguar.well being
Napo Prescribed drugs, go to www.napopharma.com
Napo Therapeutics, go to napotherapeutics.com
Magdalena Biosciences, go to magdalenabiosciences.com
Go to the Make Most cancers Much less Shitty affected person advocacy program at makecancerlessshitty.com and on X, Fb & Instagram
Ahead-Trying Statements
Sure statements on this press launch represent “forward-looking statements.” These embody statements concerning the expectation that Jaguar will present the outcomes of the OnTarget trial and updates on the corporate’s most cancers supportive care portfolio on July 23, 2024, and the expectation that Jaguar will maintain an investor webcast on July 23, 2024. In some instances, you may establish forward-looking statements by phrases reminiscent of “could,” “will,” “ought to,” “anticipate,” “plan,” “goal,” “anticipate,” “might,” “intend,” “goal,” “mission,” “ponder,” “imagine,” “estimate,” “predict,” “potential” or “proceed” or the destructive of those phrases or different comparable expressions. The forward-looking statements on this launch are solely predictions. Jaguar has primarily based these forward-looking statements largely on its present expectations and projections about future occasions. These forward-looking statements communicate solely as of the date of this launch and are topic to quite a lot of dangers, uncertainties and assumptions, a few of which can’t be predicted or quantified and a few of that are past Jaguar’s management. Besides as required by relevant regulation, Jaguar doesn’t plan to publicly replace or revise any forward-looking statements contained herein, whether or not on account of any new info, future occasions, modified circumstances or in any other case.
1 Moschen AR, Sammy Y, Marjenberg Z, Heptinstall AB, Pooley N, Marczewska AM. The Underestimated and Neglected Burden of Diarrhea and Constipation in Most cancers Sufferers. Curr Oncol Rep. 2022;24(7):861-874. doi:10.1007/s11912-022-01267-3
2 American Most cancers Society. Most cancers Info & Figures 2024. Accessible: https://www.most cancers.org/content material/dam/cancer-org/analysis/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf Accessed June 10, 2024.
3 Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impression of cancer-related diarrhea on adjustments in most cancers remedy patterns. J Clin Oncol. 2021; 39:15_suppl, 12111-12111.
4 The Oral Most cancers Basis. Mucositis. Accessed March 26, 2024. Accessible at https://oralcancerfoundation.org/issues/mucositis/
5 Pulito C, Cristaudo A, Porta CL, et al. Oral mucositis: the hidden facet of most cancers remedy. J Exp Clin Most cancers Res. 39, 210 (2020). https://doi.org/10.1186/s13046-020-01715-7
6 Oncology Nursing Society (ONS): https://www.ons.org/pep/mucositis
CONTACT:
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Well being
